Curis (CRIS) Competitors $0.50 +0.01 (+2.29%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.51 +0.01 (+2.55%) As of 05/22/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRIS vs. DOMH, SGMO, BOLT, AMGN, and GILDShould you buy Curis stock or one of its competitors? MarketBeat compares Curis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Curis include Dominari (DOMH), Sangamo Therapeutics (SGMO), Bolt Biotherapeutics (BOLT), Amgen (AMGN), and Gilead Sciences (GILD). These companies are all part of the "biotechnology" industry. CRIS vs. DOMHCRIS vs. SGMOCRIS vs. BOLTCRIS vs. AMGNCRIS vs. GILDHow does Curis compare to Dominari?Dominari (NASDAQ:DOMH) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation. Is DOMH or CRIS more profitable? Dominari has a net margin of -31.37% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Dominari's return on equity.Company Net Margins Return on Equity Return on Assets Dominari-31.37% -206.20% -155.26% Curis -80.29%N/A -181.57% Does the media favor DOMH or CRIS? In the previous week, Curis had 2 more articles in the media than Dominari. MarketBeat recorded 2 mentions for Curis and 0 mentions for Dominari. Curis' average media sentiment score of 1.02 beat Dominari's score of 0.00 indicating that Curis is being referred to more favorably in the news media. Company Overall Sentiment Dominari Neutral Curis Positive Do analysts prefer DOMH or CRIS? Curis has a consensus price target of $17.00, indicating a potential upside of 3,291.86%. Given Curis' stronger consensus rating and higher possible upside, analysts clearly believe Curis is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Curis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, DOMH or CRIS? Dominari has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Curis has a beta of 3.08, suggesting that its share price is 208% more volatile than the broader market. Do insiders & institutionals believe in DOMH or CRIS? 42.5% of Dominari shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 55.3% of Dominari shares are owned by insiders. Comparatively, 5.4% of Curis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger earnings and valuation, DOMH or CRIS? Curis has lower revenue, but higher earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDominari$123.10M0.60-$22.43M-$4.03N/ACuris$9.44M2.07-$7.58M-$1.19N/A SummaryCuris beats Dominari on 11 of the 16 factors compared between the two stocks.How does Curis compare to Sangamo Therapeutics?Sangamo Therapeutics (NASDAQ:SGMO) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk. Does the media favor SGMO or CRIS? In the previous week, Curis had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for Curis and 0 mentions for Sangamo Therapeutics. Curis' average media sentiment score of 1.02 beat Sangamo Therapeutics' score of 0.88 indicating that Curis is being referred to more favorably in the news media. Company Overall Sentiment Sangamo Therapeutics Positive Curis Positive Which has more volatility and risk, SGMO or CRIS? Sangamo Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Curis has a beta of 3.08, meaning that its share price is 208% more volatile than the broader market. Which has better valuation and earnings, SGMO or CRIS? Curis has lower revenue, but higher earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSangamo Therapeutics$39.55M1.83-$122.93M-$0.38N/ACuris$9.44M2.07-$7.58M-$1.19N/A Do institutionals and insiders believe in SGMO or CRIS? 56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 5.4% of Curis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer SGMO or CRIS? Sangamo Therapeutics presently has a consensus target price of $5.50, indicating a potential upside of 3,055.48%. Curis has a consensus target price of $17.00, indicating a potential upside of 3,291.86%. Given Curis' stronger consensus rating and higher probable upside, analysts plainly believe Curis is more favorable than Sangamo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75Curis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is SGMO or CRIS more profitable? Curis has a net margin of -80.29% compared to Sangamo Therapeutics' net margin of -310.81%. Curis' return on equity of 0.00% beat Sangamo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics-310.81% -2,662.06% -132.12% Curis -80.29%N/A -181.57% SummaryCuris beats Sangamo Therapeutics on 10 of the 15 factors compared between the two stocks.How does Curis compare to Bolt Biotherapeutics?Curis (NASDAQ:CRIS) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation. Which has stronger valuation & earnings, CRIS or BOLT? Curis has higher revenue and earnings than Bolt Biotherapeutics. Curis is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCuris$9.44M2.07-$7.58M-$1.19N/ABolt Biotherapeutics$6.50M1.46-$33.38M-$16.33N/A Which has more risk & volatility, CRIS or BOLT? Curis has a beta of 3.08, indicating that its share price is 208% more volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Do insiders and institutionals have more ownership in CRIS or BOLT? 30.0% of Curis shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 5.4% of Curis shares are owned by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is CRIS or BOLT more profitable? Curis has a net margin of -80.29% compared to Bolt Biotherapeutics' net margin of -455.15%. Curis' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Curis-80.29% N/A -181.57% Bolt Biotherapeutics -455.15%-100.89%-48.23% Does the media prefer CRIS or BOLT? In the previous week, Curis had 2 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 2 mentions for Curis and 0 mentions for Bolt Biotherapeutics. Curis' average media sentiment score of 1.02 beat Bolt Biotherapeutics' score of 0.00 indicating that Curis is being referred to more favorably in the media. Company Overall Sentiment Curis Positive Bolt Biotherapeutics Neutral Do analysts prefer CRIS or BOLT? Curis presently has a consensus price target of $17.00, indicating a potential upside of 3,291.86%. Bolt Biotherapeutics has a consensus price target of $41.00, indicating a potential upside of 728.28%. Given Curis' higher possible upside, equities analysts plainly believe Curis is more favorable than Bolt Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Bolt Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 SummaryCuris beats Bolt Biotherapeutics on 10 of the 16 factors compared between the two stocks.How does Curis compare to Amgen?Amgen (NASDAQ:AMGN) and Curis (NASDAQ:CRIS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability. Is AMGN or CRIS more profitable? Amgen has a net margin of 20.96% compared to Curis' net margin of -80.29%. Amgen's return on equity of 137.41% beat Curis' return on equity.Company Net Margins Return on Equity Return on Assets Amgen20.96% 137.41% 13.28% Curis -80.29%N/A -181.57% Does the media favor AMGN or CRIS? In the previous week, Amgen had 51 more articles in the media than Curis. MarketBeat recorded 53 mentions for Amgen and 2 mentions for Curis. Amgen's average media sentiment score of 1.09 beat Curis' score of 1.02 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 41 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Curis 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, AMGN or CRIS? Amgen has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$37.22B4.92$7.71B$14.3723.61Curis$9.44M2.07-$7.58M-$1.19N/A Which has more volatility & risk, AMGN or CRIS? Amgen has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Curis has a beta of 3.08, meaning that its stock price is 208% more volatile than the broader market. Do insiders & institutionals hold more shares of AMGN or CRIS? 76.5% of Amgen shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 5.4% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate AMGN or CRIS? Amgen currently has a consensus target price of $355.19, suggesting a potential upside of 4.68%. Curis has a consensus target price of $17.00, suggesting a potential upside of 3,291.86%. Given Curis' higher probable upside, analysts plainly believe Curis is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 14 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 2.48Curis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryAmgen beats Curis on 14 of the 17 factors compared between the two stocks.How does Curis compare to Gilead Sciences?Gilead Sciences (NASDAQ:GILD) and Curis (NASDAQ:CRIS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability. Which has better valuation & earnings, GILD or CRIS? Gilead Sciences has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGilead Sciences$29.74B5.61$8.51B$7.3418.31Curis$9.44M2.07-$7.58M-$1.19N/A Do analysts rate GILD or CRIS? Gilead Sciences currently has a consensus price target of $156.93, indicating a potential upside of 16.80%. Curis has a consensus price target of $17.00, indicating a potential upside of 3,291.86%. Given Curis' higher possible upside, analysts plainly believe Curis is more favorable than Gilead Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gilead Sciences 0 Sell rating(s) 4 Hold rating(s) 25 Buy rating(s) 0 Strong Buy rating(s) 2.86Curis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders hold more shares of GILD or CRIS? 83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 5.4% of Curis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, GILD or CRIS? Gilead Sciences has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Curis has a beta of 3.08, indicating that its stock price is 208% more volatile than the broader market. Is GILD or CRIS more profitable? Gilead Sciences has a net margin of 30.99% compared to Curis' net margin of -80.29%. Gilead Sciences' return on equity of 48.19% beat Curis' return on equity.Company Net Margins Return on Equity Return on Assets Gilead Sciences30.99% 48.19% 18.28% Curis -80.29%N/A -181.57% Does the media prefer GILD or CRIS? In the previous week, Gilead Sciences had 77 more articles in the media than Curis. MarketBeat recorded 79 mentions for Gilead Sciences and 2 mentions for Curis. Curis' average media sentiment score of 1.02 beat Gilead Sciences' score of 0.83 indicating that Curis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 45 Very Positive mention(s) 9 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Curis 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGilead Sciences beats Curis on 12 of the 16 factors compared between the two stocks. Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition ExportMetricCurisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.10M$3.38B$6.41B$12.31BDividend YieldN/A2.28%2.76%5.31%P/E Ratio-0.4218.9321.0125.66Price / Sales2.07324.91554.5883.32Price / CashN/A131.8944.5756.72Price / Book1.527.1110.377.14Net Income-$7.58M$24.45M$3.56B$335.72M7 Day Performance2.24%3.32%5.06%3.02%1 Month Performance-17.59%2.13%3.52%2.88%1 Year Performance-74.94%63.43%34.16%35.20% Curis Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris2.5058 of 5 stars$0.50+2.3%$17.00+3,291.9%-74.8%$19.10M$9.44MN/A60News CoveragePositive NewsGap UpDOMHDominari0.336 of 5 stars$3.11+0.7%N/A-31.6%$70.44M$151.67MN/A4SGMOSangamo Therapeutics2.7823 of 5 stars$0.12-6.6%$5.50+4,514.1%-64.8%$49.38M$39.55MN/A480BOLTBolt Biotherapeutics2.6163 of 5 stars$4.68+7.3%$41.00+776.1%-23.8%$8.99M$7.70MN/A90Gap UpAMGNAmgen3.8911 of 5 stars$330.62+1.9%$356.15+7.7%+24.8%$178.51B$36.75B23.0231,500Trending NewsAnalyst Forecast Related Companies and Tools Related Companies Dominari Competitors Sangamo Therapeutics Competitors Bolt Biotherapeutics Competitors Amgen Competitors Gilead Sciences Competitors Vertex Pharmaceuticals Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRIS) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
